Literature DB >> 16206080

Whipple disease: intestinal infiltrating cells exhibit a transcriptional pattern of M2/alternatively activated macrophages.

Benoît Desnues1, Hubert Lepidi, Didier Raoult, Jean-Louis Mege.   

Abstract

Whipple disease (WD) is a rare systemic disease caused by Tropheryma whipplei and is characterized by the presence of foamy macrophages with periodic acid-Schiff-positive inclusions in tissues such as lamina propria. For the first time, we report the gene-expression profile of macrophages in intestinal lesions from a patient with WD. Microarray and real-time polymerase chain reaction revealed that genes encoding CCL18, cathepsins, scavenger receptor, interleukin-10, and lipid metabolites were up-regulated in intestinal lesions. This transcriptional pattern corresponds to that of M2/alternatively activated macrophages. Our results suggest that the T helper 2 response in the intestinal environment may account for the pathophysiological properties of WD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16206080     DOI: 10.1086/491745

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  23 in total

1.  A rare intestinal infection with systemic effects.

Authors:  Randy S Longman; Roger K Moreira; Dan R Littman; Peter H R Green; Amrita Sethi
Journal:  Gastroenterol Hepatol (N Y)       Date:  2012-01

Review 2.  Whipple's disease: a macrophage disease.

Authors:  Benoît Desnues; Melanie Ihrig; Didier Raoult; Jean-Louis Mege
Journal:  Clin Vaccine Immunol       Date:  2006-02

3.  Cytokine genetic profile in Whipple's disease.

Authors:  F Biagi; C Badulli; G E Feurle; C Müller; V Moos; T Schneider; T Marth; J Mytilineos; F Garlaschelli; A Marchese; L Trotta; P I Bianchi; M Di Stefano; A L Cremaschi; A De Silvestri; L Salvaneschi; M Martinetti; G R Corazza
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-07-31       Impact factor: 3.267

4.  Haemophilus ducreyi-induced interleukin-10 promotes a mixed M1 and M2 activation program in human macrophages.

Authors:  Wei Li; Barry P Katz; Stanley M Spinola
Journal:  Infect Immun       Date:  2012-10-01       Impact factor: 3.441

Review 5.  Clinical Manifestations, Treatment, and Diagnosis of Tropheryma whipplei Infections.

Authors:  Ruben A V Dolmans; C H Edwin Boel; Miangela M Lacle; Johannes G Kusters
Journal:  Clin Microbiol Rev       Date:  2017-04       Impact factor: 26.132

6.  Role of dendritic cells in the pathogenesis of Whipple's disease.

Authors:  Katina Schinnerling; Anika Geelhaar-Karsch; Kristina Allers; Julian Friebel; Kristina Conrad; Christoph Loddenkemper; Anja A Kühl; Ulrike Erben; Ralf Ignatius; Verena Moos; Thomas Schneider
Journal:  Infect Immun       Date:  2014-11-10       Impact factor: 3.441

7.  Peripheral T-Cell Reactivity to Heat Shock Protein 70 and Its Cofactor GrpE from Tropheryma whipplei Is Reduced in Patients with Classical Whipple's Disease.

Authors:  Lucia Trotta; Kathleen Weigt; Katina Schinnerling; Anika Geelhaar-Karsch; Gerrit Oelkers; Federico Biagi; Gino Roberto Corazza; Kristina Allers; Thomas Schneider; Ulrike Erben; Verena Moos
Journal:  Infect Immun       Date:  2017-07-19       Impact factor: 3.441

8.  Epidemiology of Whipple's Disease in the USA Between 2012 and 2017: A Population-Based National Study.

Authors:  Jamie Ann Elchert; Emad Mansoor; Mohannad Abou-Saleh; Gregory S Cooper
Journal:  Dig Dis Sci       Date:  2018-11-28       Impact factor: 3.199

9.  IL-16 promotes T. whipplei replication by inhibiting phagosome conversion and modulating macrophage activation.

Authors:  Eric Ghigo; Abdoulaye Oury Barry; Lionel Pretat; Khatoun Al Moussawi; Benoît Desnues; Christian Capo; Hardy Kornfeld; Jean-Louis Mege
Journal:  PLoS One       Date:  2010-10-21       Impact factor: 3.240

10.  Type I interferon induction is detrimental during infection with the Whipple's disease bacterium, Tropheryma whipplei.

Authors:  Khatoun Al Moussawi; Eric Ghigo; Ulrich Kalinke; Lena Alexopoulou; Jean-Louis Mege; Benoit Desnues
Journal:  PLoS Pathog       Date:  2010-01-15       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.